The great coverage by the media will only help enlighten the general public on the benefits of TPM as a delivery platform.
The negative reporting by Criterion (Tim Boreham) of the Australian only shows his ignorance on the subject of TPM.
Tim reports that "Phosphagenics' technology is a variant of Metabolic's fat-busting molecule AOD9604, which failed in oral trials."
To tie Phosphagenic's technology as a variant of Metabolic's AOD9604 is grossly misleading and only shows up poor and hasty reporting with no real understanding of POH's technology.
pofaced reporting on poh
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 55 | 89268918 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 59834650 | 19 |
View Market Depth
| Last trade - 16.12pm 29/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable